Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and SX-682 in Resectable Pancreatic Cancer
NCT05604560Phase 2Recruiting
- Start
- Nov 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, SX-682 in pancreatic adenocarcinoma (PDAC). Started Nov 2023; status: recruiting.
02
Drugs
tislelizumabSX-682
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05604560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05604560.